Published in Harm Reduct J on July 29, 2009
Denial of pain medication by health care providers predicts in-hospital illicit drug use among individuals who use illicit drugs. Pain Res Manag (2015) 0.77
Illicit drug use in acute care settings. Drug Alcohol Rev (2015) 0.76
Contingencies of the will: Uses of harm reduction and the disease model of addiction among health care practitioners. Health (London) (2014) 0.75
Willingness to access an in-hospital supervised injection facility among hospitalized people who use illicit drugs. J Hosp Med (2015) 0.75
Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS (1997) 9.08
Access to highly active antiretroviral therapy for injection drug users: adherence, resistance, and death. Cad Saude Publica (2006) 6.23
HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet (1996) 5.43
Safer injection facility use and syringe sharing in injection drug users. Lancet (2005) 3.85
Hospital utilization and costs in a cohort of injection drug users. CMAJ (2001) 3.48
Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet (1997) 2.97
High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco. Clin Infect Dis (2000) 2.71
Safe injection facilities in Canada: is it time? CMAJ (2001) 2.31
Leaving hospital against medical advice among HIV-positive patients. CMAJ (2002) 2.24
The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS (2000) 2.20
High rates of primary care and emergency department use among injection drug users in Vancouver. J Public Health (Oxf) (2004) 1.95
Who leaves against medical advice? J Gen Intern Med (1995) 1.89
Attendance at supervised injecting facilities and use of detoxification services. N Engl J Med (2006) 1.83
Chronic illicit drug use, health services utilization and the cost of medical care. Soc Sci Med (2000) 1.76
Drug treatment courts in Canada: an evidence-based review. HIV AIDS Policy Law Rev (2007) 1.59
Harm reduction: come as you are. Addict Behav (1997) 1.50
Prevalence and correlates of abscesses among a cohort of injection drug users. Harm Reduct J (2005) 1.45
HIV-positive injection drug users who leave the hospital against medical advice: the mitigating role of methadone and social support. J Acquir Immune Defic Syndr (2004) 1.27
Predictors of hospitalization for injection drug users seeking care for soft tissue infections. J Gen Intern Med (2007) 1.20
Sociodemographic disparities in access to addiction treatment among a cohort of Vancouver injection drug users. Subst Use Misuse (2005) 1.10
An invisible barrier to integrating HIV primary care with harm reduction services: philosophical clashes between the harm reduction and medical models. Public Health Rep (2004) 1.06
Injection frequency mediates health service use among persons with a history of drug injection. Drug Alcohol Depend (2003) 0.98
Predictors of early hospital readmission in HIV-infected patients with pneumonia. J Gen Intern Med (2003) 0.97
Changing hospital policy from the wards: an introduction to health policy education. Acad Med (2008) 0.88
Getting clean and harm reduction: adversarial or complementary issues for injection drug users. Cad Saude Publica (2006) 0.88
The definition of harm reduction. Drug Alcohol Rev (1998) 0.84
Dr. Peter Centre - removing barriers to health care services. Nurs BC (2002) 0.83
The Dr. Peter Centre. Harm reduction nursing. Can Nurse (2003) 0.82
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet (2010) 12.82
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 7.49
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet (2006) 7.17
Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ (2009) 6.03
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 5.79
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS (2003) 5.53
Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS (2002) 5.21
Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med (2002) 4.77
Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis (2004) 4.55
Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L. Ann Intern Med (2003) 4.46
Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ (2003) 4.38
Social and structural violence and power relations in mitigating HIV risk of drug-using women in survival sex work. Soc Sci Med (2007) 4.14
Structural and environmental barriers to condom use negotiation with clients among female sex workers: implications for HIV-prevention strategies and policy. Am J Public Health (2009) 3.85
Safer injection facility use and syringe sharing in injection drug users. Lancet (2005) 3.85
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. CMAJ (2002) 3.70
The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr (2009) 3.67
Changes in Canadian heroin supply coinciding with the Australian heroin shortage. Addiction (2006) 3.65
Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study. Harm Reduct J (2006) 3.49
Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis (2008) 3.38
Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr (2006) 3.38
Rationale for evaluating North America's first medically supervised safer-injecting facility. Lancet Infect Dis (2004) 3.20
Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ (2003) 3.19
Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet (2011) 3.14
Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis (2010) 3.12
The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility. Int J Drug Policy (2008) 3.05
Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS (2007) 3.04
Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology (2002) 2.99
Does ratification of human-rights treaties have effects on population health? Lancet (2009) 2.93
Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog (2007) 2.81
Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA (2008) 2.77
Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme. AIDS (2002) 2.74
Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr (2005) 2.74
Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction (2010) 2.65
Displacement of Canada's largest public illicit drug market in response to a police crackdown. CMAJ (2004) 2.63
Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. CMAJ (2004) 2.62
A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis (2006) 2.61
Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis (2011) 2.55
Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Drug Alcohol Depend (2006) 2.53
Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs. CMAJ (2009) 2.51
When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. Lancet Infect Dis (2005) 2.48
Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis (2005) 2.42
The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS (2007) 2.39
The impact of a police presence on access to needle exchange programs. J Acquir Immune Defic Syndr (2003) 2.37
Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend (2006) 2.33
CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 2.32
Binge drug use independently predicts HIV seroconversion among injection drug users: implications for public health strategies. Subst Use Misuse (2006) 2.22
A review of barriers and facilitators of HIV treatment among injection drug users. AIDS (2008) 2.21
Impact of supply-side policies for control of illicit drugs in the face of the AIDS and overdose epidemics: investigation of a massive heroin seizure. CMAJ (2003) 2.18
Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS (2008) 2.14
Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes. Antivir Ther (2004) 2.14
AIDS incidence and AIDS-related mortality in British Columbia, Canada, between 1981 and 2013: a retrospective study. Lancet HIV (2015) 2.09
A call for evidence-based medical treatment of opioid dependence in the United States and Canada. Health Aff (Millwood) (2013) 2.09
Food insecurity and hunger are prevalent among HIV-positive individuals in British Columbia, Canada. J Nutr (2005) 2.08
Potential use of safer injecting facilities among injection drug users in Vancouver's Downtown Eastside. CMAJ (2003) 2.08
Homelessness and unstable housing associated with an increased risk of HIV and STI transmission among street-involved youth. Health Place (2009) 2.07
Summary of findings from the evaluation of a pilot medically supervised safer injecting facility. CMAJ (2006) 2.06
Public injecting and the need for 'safer environment interventions' in the reduction of drug-related harm. Addiction (2006) 2.06
Adverse effects of antiretroviral therapy for HIV infection. CMAJ (2004) 2.04
Validating a shortened depression scale (10 item CES-D) among HIV-positive people in British Columbia, Canada. PLoS One (2012) 2.02
Syringe sharing and HIV incidence among injection drug users and increased access to sterile syringes. Am J Public Health (2010) 2.00
Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis (2012) 2.00
Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. AIDS (2006) 1.98
Combination antiretroviral therapy in population affected by conflict: outcomes from large cohort in northern Uganda. BMJ (2009) 1.98
Income generating activities of people who inject drugs. Drug Alcohol Depend (2007) 1.95
Impact of neighborhood-level socioeconomic status on HIV disease progression in a universal health care setting. J Acquir Immune Defic Syndr (2008) 1.94